Accuray's TomoTherapy Superior To Conventional Radiotherapy In Preserving Heart, Lung Functioning
Accuray Incorporated (NASDAQ: ARAY) announced data from a Phase 3 TomoBreast trial of TomoTherapy System (TT) versus conventional post-surgery radiotherapy (CR) for breast cancer designed to test the hypothesis that TT might reduce lung-heart toxicity.
Benzinga ·
Benzinga
